Drugs / RBD1016
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05017116 | Aug 2021 → Oct 2023 | chronic hepatitis B virus infection | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04685564 | Feb → Sep 2021 | — | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06649266 | Aug 2024 → Sep 2026 overdue | hepatitis D virus infection | Ribocure Pharmaceuticals AB | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05961098 | Oct 2023 → Apr 2025 | chronic hepatitis B virus infection | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-24 | Ribocure Pharmaceuticals AB | Regulatory Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection ribocure.com ↗
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection. |
| 2024-03-28 | Ribocure Pharmaceuticals AB | Regulatory Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA ribocure.com ↗
Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. |
| 2023-05-19 | Ribocure Pharmaceuticals AB | Regulatory Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial. ribocure.com ↗
Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial to evaluate efficacy and safety of its novel siRNA asset for treatment of chronic hepatitis B infection. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-24 | Ribocure Pharmaceuticals AB | Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection ribocure.com ↗ |
| 2024-05-17 | Ribocure Pharmaceuticals AB | Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe ribocure.com ↗ |
| 2024-03-28 | Ribocure Pharmaceuticals AB | Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA ribocure.com ↗ |
| 2023-05-19 | Ribocure Pharmaceuticals AB | Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial. ribocure.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBD1016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05961098 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of RBD1016” NCT04685564 ↗ |